Mysteries and Mishaps - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Mysteries and Mishaps


Pharmaceutical Technology

Disappearing act


Control
"Our anti-acid product had a formulation that included simethicone as an anti-gas ingredient," reports our GMP Agent-in-Place. On one particular occasion, the batch record clearly showed that simethicone had been added and the event was witnessed. "But when the finished product was tested for simethicone, it failed miserably. No simethicone was detected!" When repeated testing confirmed no simethicone present, the employees involved were disciplined and the batch was rejected.

Says our GMP Agent-in-Place, "We never found out what really happened."

A lot to miss

"It was a typical blow–fill–seal machine," reports our GMP Agent-in-Place. The automated machine took plastic resin, heated it, blow-molded the plastic, filled the resulting container, and heat-sealed the plastic container. The lot number and expiration date were debossed into the plastic using metal inserts in the molds containing the required information.

On one particular operation, there were 30 molds used simultaneously. "The operator had trouble removing one lot number. One out of the 30 plates had to be swapped out and the operator didn't do it," reports our GMP Agent-in-Place. "The operator evidently forgot about it, and during line set-up checks the mistake was never caught." In-process checks by manufacturing and quality personnel missed this lot number as well, and the batch was merrily released.

"Then the complaints came in," grumps our GMP Agent, "and it was clear what had happened. The five connected containers contained four matching lot numbers and one different lot number. The different lot number was for the previous lot on the machine."

"The resulting recall was a no brainer," reports our Agent. "Our corrective actions included instituting a system to put a 'blank' set of molded containers in the batch record to show the correct lot numbers on set-up and to be verified on the floor by the manufacturing supervisor and the quality assurance floor inspector. The batch record auditors then could provide a second check on this during batch record review and product release."

WFI: warrant for inspection

"It started out as a routine FDA inspection," reports our GMP Agent-in-Place. "Then the FDA inspector looked into a mechanical space that had a variety of piping installed. With black iron piping connected with threaded fittings to stainless steel piping and a 4-foot dead leg, it was hard to tell what was what."

By the time the inspector got through with his questions, he determined that all this piping was part of the water-for-injection (WFI) system. Then, he wanted to take a picture of the mechanical space. "Our policy was that no one took pictures, which the inspector knew, so we refused," says our Agent.

"We told the FDA inspector that we would acknowledge the description, and that a picture wasn't needed. But he was adamant and left, only to return with a warrant and a Federal Marshall!"

The warrant allowed the inspector to take a picture of the mechanical space. Our site vice-president agreed to allow the picture, and added that the marshall wasn't needed any more.

"Nope," said the Federal Marshall, "I go with the camera until the warrant is served."

"So we all gowned up in cleanroom jumpsuits, even the Federal Marshall and his gun, and went for the picture," reports our GMP Agent. "A year and about $1 million later, we had a new water-for-injection system."

Pharmaceutical Technology's monthly "Agent-in-Place" column distills true-life cautionary tales from the secret files of Control, a senior compliance officer. If you have a story of clueless operators, oblivious management, inopportune lapses of judgment, or Murphy's Law in action, please send it to Control at

We won't use any names, but if we do use your tale of disaster, courage, or just plain weirdness, Control will send you a coveted Pharmaceutical Technology t-shirt.

ADVERTISEMENT

RELATED CONTENT
FDA's CMC Pilot Program Moves Forward
FDA Sets Guidance Agenda
A Compliance Perspective on Dissolution Method Validation for Immediate-Release Solid Oral Dosage Forms on Automated Instrumentation
21 CFR Part 11 Revision Delayed, But Moves Forward
Qualification, Validation, and Verification
blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here